A018620 Stock Overview
Engages veterinary medicines, microbial technology, and vaccines business in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
WooGene B&G Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩880.00 |
| 52 Week High | ₩1,216.00 |
| 52 Week Low | ₩830.00 |
| Beta | 0.72 |
| 1 Month Change | -2.65% |
| 3 Month Change | -2.22% |
| 1 Year Change | -22.12% |
| 3 Year Change | -57.89% |
| 5 Year Change | -49.71% |
| Change since IPO | -58.36% |
Recent News & Updates
These 4 Measures Indicate That WooGene B&G (KOSDAQ:018620) Is Using Debt Extensively
Dec 17
WooGene B&G Co., Ltd's (KOSDAQ:018620) Share Price Could Signal Some Risk
Aug 06Recent updates
These 4 Measures Indicate That WooGene B&G (KOSDAQ:018620) Is Using Debt Extensively
Dec 17WooGene B&G Co., Ltd's (KOSDAQ:018620) Share Price Could Signal Some Risk
Aug 06WooGene B&G (KOSDAQ:018620) Takes On Some Risk With Its Use Of Debt
Apr 06A Look At WooGene B&G's (KOSDAQ:018620) Share Price Returns
Feb 12Would WooGene B&G (KOSDAQ:018620) Be Better Off With Less Debt?
Dec 21Shareholder Returns
| A018620 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -0.6% | -2.1% | 2.2% |
| 1Y | -22.1% | -4.8% | -5.7% |
Return vs Industry: A018620 underperformed the KR Pharmaceuticals industry which returned -4.8% over the past year.
Return vs Market: A018620 underperformed the KR Market which returned -5.7% over the past year.
Price Volatility
| A018620 volatility | |
|---|---|
| A018620 Average Weekly Movement | 2.4% |
| Pharmaceuticals Industry Average Movement | 4.0% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.6% |
Stable Share Price: A018620 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A018620's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1977 | 92 | Seokjin Kang | www.woogenebng.com |
WooGene B&G Co., Ltd. engages veterinary medicines, microbial technology, and vaccines business in South Korea and internationally. It offers antibiotic, vaccine, nutrient, anti-inflammation, metabolic stimulant, and iron supplement products for swine, poultry, cattle, aquatic animals, companion animals, and raw materials, as well as operates vaccine research center. The company was formerly known as WooJin Co., Ltd.
WooGene B&G Co., Ltd Fundamentals Summary
| A018620 fundamental statistics | |
|---|---|
| Market cap | ₩25.42b |
| Earnings (TTM) | ₩1.24b |
| Revenue (TTM) | ₩58.64b |
20.5x
P/E Ratio0.4x
P/S RatioIs A018620 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A018620 income statement (TTM) | |
|---|---|
| Revenue | ₩58.64b |
| Cost of Revenue | ₩40.54b |
| Gross Profit | ₩18.10b |
| Other Expenses | ₩16.86b |
| Earnings | ₩1.24b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 42.95 |
| Gross Margin | 30.86% |
| Net Profit Margin | 2.12% |
| Debt/Equity Ratio | 40.4% |
How did A018620 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/23 00:57 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
WooGene B&G Co., Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.